Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
Tóm tắt
Reexpansion of CAR T cells led to further investigations which confirmed the clonal nature of this expansion.
Từ khóa
Tài liệu tham khảo
Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866
Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447
Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919
Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208
Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048], Blood, 124, 188, 10.1182/blood-2014-05-552729
Mueller, 2018, Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia, Clin Cancer Res, 24, 6175, 10.1158/1078-0432.CCR-18-0758
Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z
Haso, 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121, 1165, 10.1182/blood-2012-06-438002
Long, 2013, Lessons learned from a highly-active CD22-specific chimeric antigen receptor, OncoImmunology, 2, e23621, 10.4161/onci.23621
Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441
De Ravin, 2016, Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency, Sci Transl Med, 8, 335ra57, 10.1126/scitranslmed.aad8856
Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547
Wu, 2003, Transcription start regions in the human genome are favored targets for MLV integration, Science, 300, 1749, 10.1126/science.1083413
De Ravin, 2014, Enhancers are major targets for murine leukemia virus vector integration, J Virol, 88, 4504, 10.1128/JVI.00011-14
LaFave, 2014, MLV integration site selection is driven by strong enhancers and active promoters, Nucleic Acids Res, 42, 4257, 10.1093/nar/gkt1399
Schröder, 2002, HIV-1 integration in the human genome favors active genes and local hotspots, Cell, 110, 521, 10.1016/S0092-8674(02)00864-4
Maldarelli, 2014, HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells, Science, 345, 179, 10.1126/science.1254194
Wagner, 2014, HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection, Science, 345, 570, 10.1126/science.1256304
Zufferey, 1998, Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery, J Virol, 72, 9873, 10.1128/JVI.72.12.9873-9880.1998
Cornetta, 2018, Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products, Mol Ther, 26, 280, 10.1016/j.ymthe.2017.09.008
Cavazzana-Calvo, 2010, Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia, Nature, 467, 318, 10.1038/nature09328
Cornetta, 2018, Screening clinical cell products for replication competent retrovirus: the National Gene Vector Biorepository Experience, Mol Ther Methods Clin Dev, 10, 371, 10.1016/j.omtm.2018.08.006
Schmitz, 2009, Activation of T cells: releasing the brakes by proteolytic elimination of Cbl-b, Sci Signal, 2, pe38, 10.1126/scisignal.276pe38
Naramura, 1998, Altered thymic positive selection and intracellular signals in Cbl-deficient mice, Proc Natl Acad Sci USA, 95, 15547, 10.1073/pnas.95.26.15547
Stromnes, 2010, Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice, J Clin Invest, 120, 3722, 10.1172/JCI41991
Chiang, 2007, Ablation of Cbl-b provides protection against transplanted and spontaneous tumors, J Clin Invest, 117, 1029, 10.1172/JCI29472
Hinterleitner, 2012, Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model, PLoS One, 7, e44295, 10.1371/journal.pone.0044295
Zha, 2007, An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells, Cell Immunol, 247, 95, 10.1016/j.cellimm.2007.07.006
Peer, 2017, Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition, Oncotarget, 8, 41841, 10.18632/oncotarget.18360